MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - miscellaneous
- DR. DATSONS LABS - NATCO PHARMA
DR. DATSONS LABS vs NATCO PHARMA - Comparison Results
Current Valuations
| DR. DATSONS LABS | NATCO PHARMA | DR. DATSONS LABS/ NATCO PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | -10.9 | 34.4 | - | View Chart |
| P/BV | x | 0.2 | 4.9 | 3.3% | View Chart |
| Dividend Yield | % | 0.0 | 0.7 | - |
Financials
 DR. DATSONS LABS  NATCO PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DR. DATSONS LABS Mar-14 |
NATCO PHARMA Mar-19 |
DR. DATSONS LABS/ NATCO PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 126 | 849 | 14.8% | |
| Low | Rs | 31 | 557 | 5.5% | |
| Sales per share (Unadj.) | Rs | 133.0 | 573.8 | 23.2% | |
| Earnings per share (Unadj.) | Rs | 0.2 | 176.0 | 0.1% | |
| Cash flow per share (Unadj.) | Rs | 6.6 | 198.2 | 3.3% | |
| Dividends per share (Unadj.) | Rs | 0 | 6.25 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 0.9 | 0.0% | |
| Book value per share (Unadj.) | Rs | 128.8 | 842.7 | 15.3% | |
| Shares outstanding (eoy) | m | 31.66 | 36.50 | 86.7% | |
| Bonus/Rights/Conversions | FCCB | BB | - | ||
| Price / Sales ratio | x | 0.6 | 1.2 | 48.0% | |
| Avg P/E ratio | x | 516.1 | 4.0 | 12,921.5% | |
| P/CF ratio (eoy) | x | 11.8 | 3.5 | 333.9% | |
| Price / Book Value ratio | x | 0.6 | 0.8 | 72.8% | |
| Dividend payout | % | 0 | 3.6 | 0.0% | |
| Avg Mkt Cap | Rs m | 2,477 | 25,660 | 9.7% | |
| No. of employees | `000 | NA | 5.0 | 0.0% | |
| Total wages/salary | Rs m | 56 | 3,559 | 1.6% | |
| Avg. sales/employee | Rs Th | NM | 4,225.3 | - | |
| Avg. wages/employee | Rs Th | NM | 718.0 | - | |
| Avg. net profit/employee | Rs Th | NM | 1,295.9 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 4,211 | 20,945 | 20.1% | |
| Other income | Rs m | 79 | 1,302 | 6.0% | |
| Total revenues | Rs m | 4,289 | 22,247 | 19.3% | |
| Gross profit | Rs m | 569 | 7,948 | 7.2% | |
| Depreciation | Rs m | 204 | 810 | 25.2% | |
| Interest | Rs m | 430 | 193 | 222.9% | |
| Profit before tax | Rs m | 13 | 8,247 | 0.2% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | -2 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 6 | 1,823 | 0.3% | |
| Profit after tax | Rs m | 5 | 6,424 | 0.1% | |
| Gross profit margin | % | 13.5 | 37.9 | 35.6% | |
| Effective tax rate | % | 48.0 | 22.1 | 217.3% | |
| Net profit margin | % | 0.1 | 30.7 | 0.4% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 6,852 | 23,472 | 29.2% | |
| Current liabilities | Rs m | 6,711 | 7,287 | 92.1% | |
| Net working cap to sales | % | 3.3 | 77.3 | 4.3% | |
| Current ratio | x | 1.0 | 3.2 | 31.7% | |
| Inventory Days | Days | 161 | 92 | 174.5% | |
| Debtors Days | Days | 318 | 88 | 361.0% | |
| Net fixed assets | Rs m | 3,673 | 18,648 | 19.7% | |
| Share capital | Rs m | 317 | 365 | 86.7% | |
| "Free" reserves | Rs m | 3,761 | 34,525 | 10.9% | |
| Net worth | Rs m | 4,078 | 30,760 | 13.3% | |
| Long term debt | Rs m | 1,671 | 0 | - | |
| Total assets | Rs m | 12,633 | 43,031 | 29.4% | |
| Interest coverage | x | 1.0 | 43.7 | 2.4% | |
| Debt to equity ratio | x | 0.4 | 0 | - | |
| Sales to assets ratio | x | 0.3 | 0.5 | 68.5% | |
| Return on assets | % | 3.4 | 15.4 | 22.4% | |
| Return on equity | % | 0.1 | 20.9 | 0.6% | |
| Return on capital | % | 7.7 | 27.4 | 28.0% | |
| Exports to sales | % | 22.9 | 0 | - | |
| Imports to sales | % | 14.3 | 0 | - | |
| Exports (fob) | Rs m | 964 | NA | - | |
| Imports (cif) | Rs m | 602 | NA | - | |
| Fx inflow | Rs m | 964 | 11,536 | 8.4% | |
| Fx outflow | Rs m | 607 | 2,939 | 20.7% | |
| Net fx | Rs m | 357 | 8,597 | 4.2% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,345 | 6,688 | 20.1% | |
| From Investments | Rs m | -2,256 | -6,122 | 36.8% | |
| From Financial Activity | Rs m | -1,200 | -509 | 235.7% | |
| Net Cashflow | Rs m | -2,111 | 66 | -3,198.0% | |
Share Holding
| Indian Promoters | % | 4.5 | 52.0 | 8.7% | |
| Foreign collaborators | % | 0.0 | 1.5 | - | |
| Indian inst/Mut Fund | % | 0.0 | 7.8 | - | |
| FIIs | % | 1.4 | 16.6 | 8.1% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 94.1 | 26.0 | 361.9% | |
| Shareholders | 20,807 | 25,395 | 81.9% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DR. DATSONS LABS With: ALEMBIC PHARMA DISHMAN PHARMA J.B.CHEMICALS TORRENT PHARMA BIOCON
Compare DR. DATSONS LABS With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Sensex Ends at Record High; Tata Motors and Adani Ports Among Top Nifty Gainers(Closing)
Indian share markets extended gains to the second day today and ended at record-high levels with Nifty ending above 14,600-mark.
Related Views on News
NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)
Feb 17, 2020 | Updated on Feb 17, 2020For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)
May 28, 2019 | Updated on May 28, 2019For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)
Feb 14, 2019 | Updated on Feb 14, 2019For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
MSTC IPO: Should You Bet on This State-Run E-Commerce Player? (IPO)
Mar 13, 2019Should you subscribe to the IPO of MSPC Limited?
More Views on NewsMost Popular
'Essential' Smallcap Stock Recommendations(Profit Hunter)
Jan 8, 2021The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
Is Nifty Forming a Top(Fast Profits Daily)
Jan 8, 2021The charts are telling the bulls to be cautious.
Why Gold Hit Lower Circuit(Fast Profits Daily)
Jan 11, 2021Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)
Jan 11, 2021Our ace stock picker is ready to capitalise on a big growth opportunity.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
DR. DATSONS LABS SHARE PRICE
May 21, 2015 (Close)
TRACK DR. DATSONS LABS
- Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DR. DATSONS LABS
DR. DATSONS LABS 8-QTR ANALYSIS
COMPARE DR. DATSONS LABS WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.